Bio / Bio Weekly Update: Bio Markets, Brain Health Clinical Trial, DeSci Equity, Psilocybin Derivative

EcosystemAugust 18, 2025

Bio Weekly Update: Bio Markets, Brain Health Clinical Trial, DeSci Equity, Psilocybin Derivative

Highlights from the last week in the biosphere:We launched Bio Markets, delivering real-time market insights on projects in the Bio ecosystem and DeSci economy, including analytics on project mindshare, growth trends and in-app trading for BioDAOs, with trading for IP-Tokens & new BioAgents coming soon.The number of...

By Bio Community

Bio Weekly Update: Bio Markets, Brain Health Clinical Trial, DeSci Equity, Psilocybin Derivative

Highlights from the last week in the biosphere:

We launched Bio Markets, delivering real-time market insights on projects in the Bio ecosystem and DeSci economy, including analytics on project mindshare, growth trends and in-app trading for BioDAOs, with trading for IP-Tokens & new BioAgents coming soon.
The number of BIO staked rose to over 125M with over 3.5% of BIO's circulating supply now staked on the protocol generating BioXP for upcoming Ignition Sales. Yapping BioXP goes live in the app this week, with a live boost campaignfor BioAgents.
Bio approved a proposal to fund a human clinical trial conducted by @Cerebrum_DAO assessing the effect of its patented supplement Percepta® on human cognition in exchange for a % of $CLAW tokens (Percepta's IP-Token).
Molecule announced it is developing its V2 protocol to bridge traditional corporate structures into DeSci and drive institutional adoption, while also launching a new product hub with prescription treatments, supplements and merch, all developed by the DeSci economy.

PsyDAO's $BeeARD project's AI scientist discovered a novel psilocybin derivative with potential to boost mitochondrial production, reduce oxidative stress & more. Dive deeper in their X Spaces with Molecule. PsyDAO also rolled out BeeARD upgrades including conversational querying, allowing users to ask for explanations of generated hypotheses, and assess funding feasibility. Pump Science also selected them to be the drug dev for the upcoming launch of the LSD compound on their platform.
Pump Science crowned Rapamycin as the new "king of the pill" after outperforming other compounds in extending worm lifespan by +35%, with plans for further testing in flies.
Quantum Biology DAO is advancing its TIRF microscopy-based quantum microscope, with a successfully calibrated high-power electromagnet for precise control of rotating magnetic fields. The optical system is nearing completion, and a recently installed three-phase power system enhances electromagnet precision, enabling accurate study of quantum effects in living cells using laser light transmitted through a thin glass cable.
SpineDAO introduced Soul Bound Tokens (SBTs) for non-transferable clinician identities to label anonymized spine care data for AI training, including a peer-review system to boost accuracy beyond general models, and rewards contributors with SPINE tokens.
Long Covid Labs shared two governance proposals: one to allocate tokens for core contributors and another outlining a 12-month budget to fund key roadmap initiatives, including the Patient Grant Fund and Patient Registry.
Curetopia hosted its weekly lab meeting to discuss the latest updates on its CureARS pipeline and compound testing on ~40 targets.
HairDAO bridged to Base, completed the primary staining of 72 tissue sections in 1 day, & spoke at the "World of Apps" event by Ethereum NYC.
AthenaDAO will host their Demo Day Premiere on August 20th showcasing advancements in AI-driven reproductive longevity, decentralized clinical trials, fertility acceleration and women’s health R&D.
Spectruth DAO had 200+ people apply for their ambassador program to help expand their PTSD mission & earn token rewards.
ReflexDAO's curation phase is now sunset with plans to launch on Bio V2. If you've curated BIO for REFLEX, it can be withdrawn in the app with no fees. Withdraw your BIO here.